StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
IOVABullishResearch Analysisnews
High materiality7/10

IOVA Shares Poised for sBLA in Lifileucel After Biomarker-Driven ORR Gains

Oct 29, 2026, 7:34 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Positive phase 2 efficacy signals, strong biomarker data, and an upcoming sBLA pathway provide a potential valuation inflection, especially if November 2026 enrollment progresses as planned; regulatory milestones could drive mid-term re-rating.

AI summary

What happened, with direct paths to the underlying reporting

Iovance Biotherapeutics disclosed Phase 2 IOV-LUN-202 results for lifileucel in non-squamous mNSCLC, posting a 24.6% ORR in 69 patients. KRAS wild-type patients reached 43.3% ORR, KRAS-mutant 11.4%, and a biomarker-enriched subgroup achieved 59.1% ORR. With Cohorts 1–2 enrollment wrapping up and a planned 2027 sBLA, the company advances a biomarker-driven registrational path, supported by a November 2026 enrollment start for precision TIL strategies.

  • IOVA: 24.6% ORR in 69 non-squamous mNSCLC; aligns with prior cohorts. Cohorts 1-2 enrollment finishing; supports 2027 sBLA.
  • KRAS wild-type: 43.3% ORR; KRAS-mutant: 11.4%. Biomarker-enriched subgroup: 59.1% ORR.
  • Biomarker-enriched, first-in-class strategy with registrational intent; enrollment begins November 2026.
  • sBLA for lifileucel in non-squamous mNSCLC targeted for 2027.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event